Onxeo is a clinical-stage biotechnology company that develops new cancer drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). The company's portfolio is based on PlatOn, its decoy oligonucleotide platform, and includes AsiDNA, a first-in-class product interfering with tumor DNA break repair, and a new family of compounds, OX400, positioned as a new-generation PARP agonists that are designed not to induce resistance and to activate the immune response. The company is convinced of the significant therapeutic potential of its decoy oligonucleotide technology and the disruptive innovation it represents, which could pave the way for a new paradigm in cancer treatment.